Literature DB >> 23045275

Telomerase reverse transcriptase promotes epithelial-mesenchymal transition and stem cell-like traits in cancer cells.

Z Liu1, Q Li, K Li, L Chen, W Li, M Hou, T Liu, J Yang, C Lindvall, M Björkholm, J Jia, D Xu.   

Abstract

Telomerase activation through induction of telomerase reverse transcriptase (hTERT) contributes to malignant transformation by stabilizing telomeres. Clinical studies demonstrate that higher hTERT expression is associated with cancer progression and poor outcomes, but the underlying mechanism is unclear. Because epithelial-mesenchymal transition (EMT) and cancer stem cells (CSCs) are key factors in cancer metastasis and relapse, and hTERT has been shown to exhibit multiple biological activities independently of its telomere-lengthening function, we address a potential role of hTERT in EMT and CSCs using gastric cancer (GC) as a model. hTERT overexpression promotes, whereas its inhibition suppresses, EMT and stemness of GC cells, respectively. Transforming growth factor (TGF)-β1 and β-catenin-mediated EMT was abolished by small interfering RNA depletion of hTERT expression. hTERT interacts with β-catenin, enhances its nuclear localization and transcriptional activity, and occupies the β-catenin target vimentin promoter. All these hTERT effects were independent of its telomere-lengthening function or telomerase activity. hTERT and EMT marker expression correlates positively in GC samples. Mouse experiments demonstrate the in vivo stimulation of hTERT on cancer cell colonization. Collectively, hTERT stimulates EMT and induces stemness of cancer cells, thereby promoting cancer metastasis and recurrence. Thus, targeting hTERT may prevent cancer progression by inhibiting EMT and CSCs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23045275     DOI: 10.1038/onc.2012.441

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  116 in total

Review 1.  The role of telomeres and telomerase reverse transcriptase isoforms in pluripotency induction and maintenance.

Authors:  Jonathan H Teichroeb; Joohwan Kim; Dean H Betts
Journal:  RNA Biol       Date:  2016-01-19       Impact factor: 4.652

2.  hTERT mediates norepinephrine-induced Slug expression and ovarian cancer aggressiveness.

Authors:  M J Choi; K H Cho; S Lee; Y J Bae; K J Jeong; S Y Rha; E J Choi; J H Park; J M Kim; J-S Lee; G B Mills; H Y Lee
Journal:  Oncogene       Date:  2014-08-25       Impact factor: 9.867

3.  Histone demethylase PHF8 promotes progression and metastasis of gastric cancer.

Authors:  Shuyan Li; Ao Sun; Xiuming Liang; Lin Ma; Li Shen; Tongyu Li; Lixin Zheng; Wenjing Shang; Wei Zhao; Jihui Jia
Journal:  Am J Cancer Res       Date:  2017-03-01       Impact factor: 6.166

4.  Ultrasonographic prediction of highly aggressive telomerase reverse transcriptase (TERT) promoter-mutated papillary thyroid cancer.

Authors:  Tae Hyuk Kim; Chang-Seok Ki; Soo Yeon Hahn; Young Lyun Oh; Hye Won Jang; Sun Wook Kim; Jae Hoon Chung; Jung Hee Shin
Journal:  Endocrine       Date:  2017-06-14       Impact factor: 3.633

5.  Fundamental insights into autosomal dominant polycystic kidney disease from human-based cell models.

Authors:  Caroline Weydert; Jean-Paul Decuypere; Humbert De Smedt; Peter Janssens; Rudi Vennekens; Djalila Mekahli
Journal:  Pediatr Nephrol       Date:  2018-09-13       Impact factor: 3.714

Review 6.  The non-canonical functions of telomerase: to turn off or not to turn off.

Authors:  Aleksandra Romaniuk; Anna Paszel-Jaworska; Ewa Totoń; Natalia Lisiak; Hanna Hołysz; Anna Królak; Sylwia Grodecka-Gazdecka; Błażej Rubiś
Journal:  Mol Biol Rep       Date:  2018-11-17       Impact factor: 2.316

Review 7.  A second chance for telomerase reverse transcriptase in anticancer immunotherapy.

Authors:  Maurizio Zanetti
Journal:  Nat Rev Clin Oncol       Date:  2016-06-01       Impact factor: 66.675

8.  TERT Promoter Hypermethylation in Gastrointestinal Cancer: A Potential Stool Biomarker.

Authors:  Li Liu; Cheng Liu; Omid Fotouhi; Yidong Fan; Kun Wang; Chuanyou Xia; Benkang Shi; Guangyong Zhang; Kexin Wang; Feng Kong; Catharina Larsson; Sanyuan Hu; Dawei Xu
Journal:  Oncologist       Date:  2017-07-28

Review 9.  Nonviral oncogenic antigens and the inflammatory signals driving early cancer development as targets for cancer immunoprevention.

Authors:  Nina J Chu; Todd D Armstrong; Elizabeth M Jaffee
Journal:  Clin Cancer Res       Date:  2015-01-26       Impact factor: 12.531

10.  Tumor suppressor SET9 guides the epigenetic plasticity of breast cancer cells and serves as an early-stage biomarker for predicting metastasis.

Authors:  M F Montenegro; L Sánchez-Del-Campo; R González-Guerrero; E Martínez-Barba; A Piñero-Madrona; J Cabezas-Herrera; J N Rodríguez-López
Journal:  Oncogene       Date:  2016-05-02       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.